This study aimed to evaluate the visual and morphological outcomes of intravitreal anti-VEGF therapy and the recurrence for idiopathic choroidal neovascularization (ICNV). This retrospective study included 35 patients (35 eyes) with ICNV from July 2012 to October 2017. All patients received 1 intravitreal anti-VEGF injection followed by pro re nata injections until there was no sign of ICNV activity. This was defined as the first follow-up period. To evaluate ICNV recurrence, we continued to follow-up 27 of the 35 patients for at least 2 years after the initial diagnosis, and the longest follow-up period was 5 years. Additional injection was performed when ICNV recurred. Best corrected visual acuity (BCVA) and central retinal thickness (CRT) were recorded and morphological improvement in optical coherence tomography (OCT) was assessed. Parameters that affect prognosis and recurrence were analysed. The mean follow-up period was 168.0 ± 34.82 weeks. Mean BCVA improved from 56.20 ± 14.13 letters at baseline to 73.31 ± 12.57 letters (P<0.01); Mean CRT decreased from 353.6 ± 98.70 μm at baseline to 273.1 ± 53.56 μm (P < 0.001) at the end of the first follow-up period. Better baseline BCVA indicated a better morphological improvement (P = 0.026) in OCT: the lesion had completely subsided with recovery of the foveal contour. Those with high baseline BCVA (more than 60 letters) showed significant resolution of CNV lesions (P = 0.036). ICNV recurred in six patients (22.2%), 1 of whom experienced 2 recurrences. The mean timing of recurrence was 90.83 ± 49.02 weeks after diagnosis. There was no significant correlation between ICNV recurrence and the morphological improvement (P = 0.633). The final BCVA in patients with recurrence did not differ from that in patients without recurrence (P = 0.065). Intravitreal anti-VEGF therapy on a pro re nata basis was effective for treating ICNV. High baseline BCVA indicated a better prognosis. Re-treatment with anti-VEGF could effectively lead to resolution of recurrent ICNV. Disease recurrence had no significant effect on final visual prognosis and had no correlation with the morphological improvement during treatment, suggesting that follow-up for subsequent monitoring should be performed in all ICNV patients.

中文翻译：

---

抗血管内皮生长因子治疗特发性脉络膜新生血管的疗效和复发率评估

这项研究旨在评估玻璃体内抗VEGF治疗的视觉和形态学结果以及特发性脉络膜新生血管形成（ICNV）的复发。这项回顾性研究纳入了2012年7月至2017年10月的35例ICNV患者（35眼）。所有患者均接受1剂玻璃体内抗VEGF注射，然后经鼻内注射直至没有ICNV活性的迹象。这被定义为第一个随访期。为了评估ICNV复发，我们对35例患者中的27例进行了首次随访，至少随访了2年，最长随访时间为5年。当ICNV复发时，进行另外的注射。记录最佳矫正视力（BCVA）和视网膜中央厚度（CRT），并评估光学相干断层扫描（OCT）的形态学改善。分析了影响预后和复发的参数。平均随访期为168.0±34.82周。平均BCVA从基线的56.20±14.13个字母提高到73.31±12.57个字母（P <0.01）; 在第一个随访期结束时，平均CRT从基线的353.6±98.70μm降低到273.1±53.56μm（P <0.001）。更好的基线BCVA表示OCT的形态学改善更好（P = 0.026）：病变已完全消退，并伴有中央凹轮廓。基线BCVA高（超过60个字母）的患者表现出CNV病变的明显消退（P = 0.036）。ICNV复发6例（22.2％），其中1例复发2。诊断后平均复发时间为90.83±49.02周。ICNV复发与形态学改善之间无显着相关性（P = 0。633）。复发患者的最终BCVA与未复发患者的最终BCVA无差异（P = 0.065）。按玻尿酸玻璃体内抗VEGF治疗有效治疗ICNV。高基线BCVA表示预后较好。抗VEGF的再治疗可以有效地导致复发性ICNV的消退。疾病复发对最终的视觉预后没有显着影响，并且与治疗期间的形态学改善没有相关性，这表明对所有ICNV患者应进行随访以进行后续监测。抗VEGF的再治疗可以有效地导致复发性ICNV的消退。疾病复发对最终的视觉预后没有显着影响，并且与治疗期间的形态学改善没有相关性，这表明对所有ICNV患者应进行随访以进行后续监测。抗VEGF的再治疗可以有效地导致复发性ICNV的消退。疾病复发对最终的视觉预后没有显着影响，并且与治疗期间的形态学改善没有相关性，这表明对所有ICNV患者应进行随访以进行后续监测。